Why is Teva Pharma stock surging today?

Teva Pharma stock surged 3.3% in pre-open trading after the company announced that its investigational anti-interleukin-15 antibody, TEV ’408, delivered a clear win in a Phase 2a clinical study targeting celiac disease.

The trial met its primary endpoint, demonstrating statistically significant and clinically meaningful prevention of gluten-induced intestinal damage compared with placebo at week 8, while also showing a favorable tolerability profile with no emerging safety signals.

The celiac disease data carry added strategic weight because TEV ’408 is already being advanced into a Phase 2b study for vitiligo, positioning the molecule as a potential multi-indication asset across autoimmune conditions.

Teva developed TEV ’408 in partnership with Royalty Pharma, which committed up to $500 million to fund its clinical development, and the company held a dedicated investor call this morning to discuss the new data — a move that amplified market attention ahead of the open.

The pre-market move comes against a broadly neutral backdrop for U.S. equities, with the S&P 500 edging up 0.1% and the Dow Jones gaining 0.3%, while the Nasdaq dipped slightly.

Teva’s pharmaceutical peers did not produce comparable company-specific catalysts today, meaning the stock’s outperformance was driven squarely by its own pipeline news rather than sector-wide momentum.

Taken together, the positive TEV ’408 readout adds a meaningful new data point to Teva’s ongoing transformation story — one that has already included a Moody’s investment-grade credit upgrade, FDA priority review for ecopipam in Tourette syndrome, and raised full-year revenue guidance — pushing the stock within striking distance of its 52-week high.